Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) – Research analysts at Svb Leerink issued their FY2021 earnings estimates for Adaptimmune Therapeutics in a research report issued on Monday, January 13th. Svb Leerink analyst J. Chang expects that the biotechnology company will post earnings per share of ($1.32) for the year.
A number of other brokerages have also recently commented on ADAP. Zacks Investment Research cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 8th. Cowen reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Thursday, November 7th. Finally, ValuEngine raised Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $5.23.
Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.03). The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $7.00 million.
Several hedge funds have recently modified their holdings of ADAP. Man Group plc grew its position in shares of Adaptimmune Therapeutics by 37.4% in the 2nd quarter. Man Group plc now owns 1,839,225 shares of the biotechnology company’s stock worth $7,394,000 after buying an additional 500,595 shares during the last quarter. Bamco Inc. NY grew its position in shares of Adaptimmune Therapeutics by 6.1% in the 2nd quarter. Bamco Inc. NY now owns 172,669 shares of the biotechnology company’s stock worth $694,000 after buying an additional 10,000 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Adaptimmune Therapeutics by 21,372.0% in the 3rd quarter. Tower Research Capital LLC TRC now owns 21,472 shares of the biotechnology company’s stock worth $32,000 after buying an additional 21,372 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of Adaptimmune Therapeutics by 5.2% in the 3rd quarter. Millennium Management LLC now owns 914,416 shares of the biotechnology company’s stock worth $1,380,000 after buying an additional 45,249 shares during the last quarter. Hedge funds and other institutional investors own 65.06% of the company’s stock.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Featured Story: Neutral Rating
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.